Copertura documentale

Il Quality Gate pubblico registra 53 supporti documentali, 4 fonti indipendenti e 11 relazioni. Questi valori misurano documentazione e provenienza, non efficacia o appropriatezza clinica.

Documenti indicizzati collegati

• Corrigendum to “Naturally derived Erythrinin C targets γ-secretase signaling to suppress triple-negative breast cancer progression and reverse paclitaxel resistance” [Phytomedicine 154 (2026) 158016] — Crossref
• Impact of SLCO1B3 767G>C (rs60140950) polymorphism on paclitaxel response in Iraqi women with breast cancer. — PubMed / NCBI
• An Insight into the Anti-Cancer Potential of N-Heterocyclic Compounds Targeting Breast Cancer — Crossref
• Impact of SLCO1B3 767G>C (rs60140950) polymorphism on paclitaxel response in Iraqi women with breast cancer — Crossref
• Inhibitory Effect and Mechanism of Paclitaxel-Loaded Magnetic Iron Oxide Nanomicrobubbles Combined with Ultrasound Therapy on Breast Cancer Xenografts in Nude Mice Running Title: the Application of Paclitaxel-Loaded Fe3O4 Nanomicrobubbles — Crossref
• Sacituzumab govitecan combined with anlotinib in metastatic triple negative breast cancer patient with repeated pleural effusion: a case report — Crossref
• MAD2L1 overexpression promotes breast cancer progression and confers resistance to paclitaxel via proteasomal stabilization — Crossref
• Acute effects of ultrasound-targeted microbubble destruction on tumor interstitial fluid pressure and intratumoral distribution of doxorubicin and nab-paclitaxel in an orthotopic breast cancer model — Crossref
• Neoadjuvant TACE combined with chemo-immunotherapy for giant triple-negative breast cancer: a case report. — PubMed / NCBI
• Case Report: Life-threatening neutropenia with absolute neutrophil count of zero after low-dose regional arterial infusion chemotherapy to lung in a patient with advanced triple-negative breast cancer after multiple lines of treatment — Crossref
• Reinforcement of Solid Lipid Nanoparticles for Targeted PD-L1 Downregulation in Breast Cancer — Crossref
• Transcriptomic Profiling of Mouse Mammary Tumors Enables Prognostic and Predictive Biomarker Discovery for Human Breast Cancer — Crossref

Collegamenti nel Knowledge Graph

• A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer — uses intervention
• Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones — uses intervention
• Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD) — uses intervention
• A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01) — uses intervention
• Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49) — uses intervention
• [18F]FLT PET/CT in Rb+ Metastatic Breast Cancer — uses intervention
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial — uses intervention
• Triple-B Study;Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Atezolizumab as First-line Treatment in Advanced Triple Negative Breast Cancer — uses intervention
• Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer — uses intervention
• Onvansertib + Paclitaxel In TNBC — uses intervention
• BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer — uses intervention
• Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer — uses intervention

Come interpretare questa pagina

Una relazione documentale non equivale a una raccomandazione. Risultati favorevoli nelle condizioni studiate, non favorevoli nelle condizioni studiate, non concordanti o con dati insufficienti restano consultabili nel motore con la loro provenienza.

Privacy

Questa pagina deriva esclusivamente dal patrimonio scientifico pubblico indicizzato. Il Publisher non usa IP, cookie, account, cronologia, fingerprint o ricerche individuali.

Quality Gate documentale: 100/100 · ultimo aggiornamento Settembre 29, 2026